RegeneRx Biopharmaceuticals, Inc. (RGRX)
OTCMKTS
· Delayed Price · Currency is USD
0.0014
0.00 (0.00%)
Jan 21, 2025, 3:00 PM EST
RGRX Revenue
RegeneRx Biopharmaceuticals had revenue of $19.19K in the quarter ending March 31, 2023, a decrease of -0.01%. This brings the company's revenue in the last twelve months to $76.76K, down -0.00% year-over-year. In the year 2022, RegeneRx Biopharmaceuticals had annual revenue of $76.76K.
Revenue (ttm)
76.76K
Revenue Growth
-0.00%
P/S Ratio
0.03
Revenue / Employee
25.59K
Employees
3
Market Cap
2.11K
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
RegeneRx Biopharmaceuticals News
- 1 year ago - RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations - PRNewsWire
- 1 year ago - RegeneRx Receives Stockholder Approval for Reverse Stock Split - PRNewsWire
- 1 year ago - RegeneRx To Extend Consent Solicitation Vote - PRNewsWire
- 1 year ago - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 - PRNewsWire
- 1 year ago - RegeneRx Issues Letter To Stockholders - PRNewsWire
- 2 years ago - Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy - PRNewsWire
- 2 years ago - Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy - PRNewsWire
- 2 years ago - RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease - PRNewsWire